Registration Options

Activity Date: 04/25/2022

Session Time and Location

The live session is complete.

Session Summary

Readily available therapeutic drug monitoring (TDM) of antipsychotic blood levels can provide evidenced-based and personalized psychopharmacologic treatment. Clozapine is the only evidence-based antipsychotic option for treatment resistant schizophrenia and schizophrenia patients with suicidality, with a wealth of data on plasma level response thresholds and the point of futility. For medications such as clozapine, patients and healthcare providers have many situations where TDM is highly relevant in making day-to-day clinical decisions, including differentiating poor adherence with ultrarapid metabolism, and optimizing levels in inadequate responders. During this session, the faculty will discuss the unique place of clozapine for treatment resistant schizophrenia, and the role of TDM in clozapine dosing during titration, and for monitoring ongoing adherence. An open microphone session will follow the presentations.

Faculty Information and Disclosures

Jonathan Meyer, MD
Rob Cotes, MD
Deanna Kelly, PharmD, BCPP
Megan Ehret, PharmD, MS, BCPP

View biographical information and disclosures

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support

Sponsored by Saladax Biomedical